Approach to patients with neurometabolic diseases who show characteristic signs and symptoms
Iranian Journal of Child Neurology,
Vol. 14 No. 3 (2020),
28 June 2020
Neurometabolic disorders are hereditary conditions mainly affect the function of the brain and the nervous system. The prevalence of these disorders is 1 in 1000 live births. Such disorders, at different ages could manifest as sepsis, hypoglycemia, and other neurologic disorders. Having similar manifestations leads to delayed diagnosis of neurometabolic disorders. A number of neurometabolic disorders have known treatments; however, to prevent long‑term complications the key factors are early diagnosis and treatment. Although a large number of neurometabolic diseases have no treatment or cure, the correct and on‑time diagnosis before death is important for parents to have plans for prenatal diagnosis. Different diagnostic procedures could be offered to parents, enzymatic procedures and determining metabolites in plasma, urine, and CSF, and molecular genetic diagnosis. Molecular genetic diagnostic procedures are expensive and could not be offered to all parents. Therefore, we aimed to design algorithms to diagnose neurometabolic disorders according to some frequent and characteristic signs and symptoms. By designing these algorithms and using them properly, we could offer diagnostic enzymatic panels. These enzymatic panels are inexpensive, therefore, could reduce the financial burden on the parents. Also, having an early diagnosis according to these panels could lead to offering more accurate and less expensive molecular genetic tests.
- Neurometabolic disorders
- enzymatic panels
How to Cite
Filiano JJ. Neurometabolic diseases in the newborn. Clin Perinatol. 2006;33(2):411-79.
Fernandes Filho JA, Shapiro BE. Tay-Sachs disease. Arch Neurol. 2004;61(9):1466-8.
Suvarna JC, Hajela SA. Cherry-red spot. J Postgrad Med. 2008;54(1):54-7.
Gieselmann V, Franken S, Klein D, Mansson JE, Sandhoff R, Lullmann Rauch R, et al. Metachromatic leukodystrophy: consequences of sulphatide accumulation. Acta Paediatr Suppl. 2003;92(443):74-9; discussion 45.
Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins. Biochim Biophys Acta. 2009;1793(4):710-25.
Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal. 2009;21(6):836-46.
Lynch DT, Czuchlewski DR. Peripheral blood findings in GM1 gangliosidosis. Blood. 2016;127(17):2161.
Pshezhetsky AV, Ashmarina M. Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Res Mol Biol. 2001;69:81-114.
Santos-Lozano A, Villamandos Garcia D, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, et al. Niemann-Pick disease treatment: a systematic review of clinical trials. Ann Transl Med. 2015;3(22):360.
Gieselmann V. Metachromatic leukodystrophy: recent research developments. J Child Neurol. 2003;18(9):591-4.
Fuchshuber A, Suormala T, Roth B, Duran M, Michalk D Baumgartner ER. Holocarboxylase synthetase deficiency: early diagnosis and management of a new case. Eur J Pediatr. 1993;152(5):446-9.
Altarescu G, Sun M, Moore DF, Smith JA, Wiggs EA, Solomon BI, et al. The neurogenetics of mucolipidosis type IV. Neurology. 2002;59(3):306-13.
Caciotti A, Di Rocco M, Filocamo M, Grossi S, Traverso F, d'Azzo A, et al. Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients. J Neurol. 2009;256(11):1911-5.
Itoh K, Naganawa Y, Matsuzawa F, Aikawa S, Doi H, Sasagasako N, et al. Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J Hum Genet. 2002;47(1):29-37.
Lin MH, Pitukcheewanont P. Mucolipidosis type II (I-cell disease) masquerading as rickets: two case reports and review of literature. J Pediatr Endocrinol Metab. 2012;25(1-2):191-5.
Matheus MG, Castillo M, Smith JK, Armao D, Towle D, Muenzer J. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology. 2004;46(8):666-72.
Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr. 2007;96(455):63-70.
Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267-77.
Achyuthan KE, Achyuthan AM. Comparative enzymology, biochemistry and pathophysiology of human exo-alpha-sialidases (neuraminidases). Comp Biochem Physiol B Biochem Mol Biol. 2001;129(1):29-64.
Ruivo R, Anne C, Sagne C, Gasnier B. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim Biophys Acta. 2009;1793(4):636-49.
Park JH, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta. 2006;1758(12):2133-8.
Cooper JD. Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr Opin Neurol. 2003;16(2):121-8.
Mondal RK, Nandi M, Datta S, Hira M. Disseminated lipogranulomatosis. Indian Pediatr. 2009;46(2):175-7.
Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet. 2003;121C(1):38-52.
Naganawa Y, Itoh K, Shimmoto M, Takiguchi K, Doi H, Nishizawa Y, et al. Molecular and structural studies of Japanese patients with sialidosis type 1. J Hum Genet. 2000;45(4):241-9.
Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358(6):605-14.
Santarelli F, Cassanello M, Enea A, Poma F, D'Onofrio V, Guala G, et al. A neonatal case of 3-hydroxy-3-methylglutaric-coenzyme A lyase deficiency. Ital J Pediatr. 2013;39:33.
Wang D, Yang H, De Braganca KC, Lu J, Yu Shih L, Briones P, et al. The molecular basis of pyruvate carboxylase deficiency: mosaicism correlates with prolonged survival. Mol Genet Metab. 2008;95(1-2):31-8.
Wolf B. Biotinidase deficiency and our champagne legacy. Gene. 2016;589(2):142-50.
Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. Biotiniase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta. 1983;131(3):273-81.
Lindner M, Kolker S, Schulze A, Christensen E, Greenberg CR, Hoffmann GF. Neonatal screening for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2004;27(6):851-9.
Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001;4(3):212-21.
Borgwardt L, Lund AM, Dali CI. Alpha-mannosidosis - a review of genetic, clinical findings and options of treatment. Pediatr Endocrinol Rev. 2014;12 Suppl 1:185-91.
Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002;25(5):399-410.
- Abstract Viewed: 72 times
- PDF Downloaded: 10 times